OrbiMed Asia leads Laekna's $18.5M series A

Laekna Therapeutics Shanghai Co. Ltd. (Shanghai, China) raised $18.5 million in a series A round led by OrbiMed Asia, with participation from AnlongMed.

Laekna said it has three candidates in Phase I-II testing to treat various cancers and drug discovery programs in cancer and liver disease, including non-alcoholic steatohepatitis (NASH) and hepatic cirrhosis...